AbCellera (Nasdaq: ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live webcast will be available on AbCellera’s Investor Relations website at: https://investors.abcellera.com/. Replay of the webcast will be available through the same link following the conference call.
About AbCellera
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. To learn more, please visit www.abcellera.com.
Source: AbCellera Biologics Inc.
| Last Trade: | US$2.42 |
| Daily Change: | -0.61 -20.13 |
| Daily Volume: | 2,981,729 |
| Market Cap: | US$714.800M |
March 25, 2025 February 27, 2025 January 13, 2025 November 07, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
